Tonix Pharmaceuticals (NasdaqCM:TNXP) FY Conference Transcript

Tonix Pharmaceuticals FY Conference Summary Company Overview - Company Name: Tonix Pharmaceuticals (NasdaqCM: TNXP) - Focus: Fully integrated pharmaceutical company with a focus on the launch of Tonmya, a treatment for fibromyalgia, and other therapeutic areas including migraine treatments [2][3] Key Products and Developments - Tonmya: - A sublingual cyclobenzaprine tablet approved for fibromyalgia treatment, launched on November 17, 2025 [4][6] - Targets disturbed sleep quality in fibromyalgia, addressing a high unmet need in a market with approximately 10 million adults affected in the U.S. [4][11] - Reported $1.4 million in net sales since launch [6] - Unique mechanism and first-in-class designation, with a focus on the 5% of prescribers who account for 70% of prescriptions [6][18] - Migraine Treatments: - Acquired two migraine products, Tosymra (sumatriptan nasal spray) and Zembrace (sumatriptan injection), but are gradually decreasing promotion of these products [19] Market Dynamics - Fibromyalgia Market: - High dissatisfaction with existing treatments, with only 3 million out of 10 million diagnosed and treated [12][13] - Potential for increased diagnosis among long COVID patients, with estimates suggesting 20-30 million may be affected [12] - Tonmya's pricing set at $1,860 per month for long-term use [18] - Challenges and Opportunities: - Need for education among prescribers about fibromyalgia and Tonmya [17][18] - Existing drugs for fibromyalgia are often misprescribed, with a significant reliance on opioids, which are not indicated for this condition [15][16] Clinical Pipeline - Upcoming Studies: - Lyme prophylactic program with promising phase one data, targeting a long-acting monoclonal antibody [27][28] - Studies for major depressive disorder and acute stress disorder funded by the U.S. Department of Defense [30] - Phase 2 study for kidney transplant treatment [31][32] Financial Position - Financial Health: - Ended the previous year with $208 million in cash and no debt, indicating a strong balance sheet [3] Conclusion - Tonix Pharmaceuticals is positioned for growth with a strong focus on addressing unmet needs in fibromyalgia and expanding its clinical pipeline. The company aims to leverage its unique product offerings and robust marketing strategies to capture a significant share of the market while navigating challenges in prescriber education and competition [33]